Sutro Biopharma confirmed that the company has appointed Ms. Connie L. Matsui, retired Executive Vice President of Biogen Idec, as Chair of the company’s Board of Directors.
Sutro Biopharma, is a clinical-stage drug discovery, development and manufacturing company using precise protein engineering and rational design, to discover and advancing next-generation oncology therapeutics. The company’s proprietary and integrated cell-free protein synthesis and site-specific conjugation platform, XpressCF+™, led to the discovery of STRO-001 and STRO-002, Sutro’s first two internally-developed ADCs.
To date, Sutro has designed cytokine-based immuno-oncology therapies, Adntibody-drug Conjugates (ADCs), vaccines and bispecific antibodies primarily directed at clinically-validated targets for which the current standard of care is suboptimal.
Innovative and Principled Leadership
Ms. Matsui brings more than 35 years of innovative and principled leadership spanning the banking, biotechnology and nonprofit sectors.
“With Sutro having multiple early clinical development programs currently in place, Connie’s experience at high-growth companies is very well suited to our vision,” said Bill Newell, Sutro’s Chief Executive Officer.
“We look forward to accessing her expertise as we continue to advance our robust clinical pipeline with a goal of creating important and meaningful products for patients. We send our special thanks to Dan Janney, Managing Director of Alta Partners, for his leadership and long-standing contributions as a member and Chair of our Board. With the appointment of Connie, Dan is stepping down from the Board,” added Newell.
Matsui brings more than 16 years of general management experience in the biotechnology industry. She retired from Biogen Idec in January 2009 as the Executive Vice President, Knowledge and Innovation Networks.
During her career Matsui served as an Executive Committee member at both Biogen Idec and IDEC Pharmaceuticals, a predecessor of Biogen Idec. She joined IDEC in 1992 and held a variety of positions, including Senior Vice President, overseeing investor relations, corporate communications, human resources, project management and strategic planning; Collaboration Chair for the late stage development and commercialization of rituximab (tradenames: Rituxan®, MabThera®) in partnership with Roche and Genentech; and Project Leader for Zevalin®, the first radioimmunotherapy approved by the U.S. Food and Drug Administration.
Prior to entering the biotechnology industry, Matsui worked for Wells Fargo Bank in general management, marketing and human resources. She is Chair and an active board member at Halozyme Therapeutics and in the past served on a number of not-for-profit boards, as well as served as National President/Board Chair of the Girl Scouts of the USA from 1999 to 2002. Ms. Matsui earned her B.A. and MBA degrees from Stanford University.
“It is an exciting time for Sutro, as the company has successfully launched its second clinical trial and has a unique technology platform with promising product opportunities,” Matsui observed. “Sutro’s technology platform has shown tremendous potential and I look forward to playing a key leadership role and working closely with Sutro’s leadership to continue evolving its pipeline.”
Matsui will serve as chair of the Nominating and Governance Committee and as a member of the Compensation Committee. She will be succeeding former Chair of the Board Daniel Janney.